Pune-based Serum Institute of India also confirmed that it has received a purchase order from the Government of India for 1.1 crore doses of its coronavirus vaccine 'Covishield'. The Indian regulator has granted restricted emergency use approval for Covishield and Covaxin vaccines.
SII facility in Pune's Pimpri Chinchwad where Covishield is being manufactured (Photo Credits: PTI)
Covishield, the coronavirus vaccine developed by the University of Oxford and AstraZeneca will be sold at Rs 200 per dose. Sources within the Serum Institute of India (SII), Oxford University and AstraZeneca's partner in India told India Today that the price of each dose of the Covid-19 vaccine "was always fixed".
"The price was always fixed. No issues of agreement. The price of the doses is fixed at Rs 200 per dose," sources said. In addition, sources also confirmed to India Today that the Covishield shipment will leave from SII's facility in Pune on Monday evening.
"Final paperwork took some time from the government side, which has now concluded," said sources.
Each dose of the Serum Institute's Covid-19 vaccine has been priced at Rs 200, excluding GST. An additional cost of Rs 10 (GST) will result in each dose costing Rs 210.
Pune-based Serum Institute of India also confirmed that it has received a purchase order from the Union Ministry of Health, Government of India. While 1.1 crore (11 million) doses of Covishield are being shipped in the first trance, the number may increase in the coming weeks.
Addressing the nation on Monday, Prime Minister Narendra Modi said India will begin the world's largest vaccination drive on January 16. "First Corona warriors and then frontline workers will be vaccinated," he said adding that India will probably approve more vaccines for the second phase of the vaccination drive.
On Monday, the Indian Medical Association (IMA) also requested all of its 3.5 lakh members to get vaccinated against Covid-19 to show the world that the vaccines approved by Indian regulators are safe and efficacious.
On January 2, the Central Drugs and Standards Committee (CDSCO) approved the University of Oxford's Covishield and Bharat Biotech's Covaxin for emergency use. Following the approval, these can now be used to vaccinate health care workers and frontline workers in India against Covid-19.
The Serum Institute of India has also roped in Pune-based Kool-ez Cold Chain Ltd to transport doses of its coronavirus vaccine throughout India. On Monday, six air-conditioned trucks will be used to transport the first consignment of Covishield doses from SII's facility in Pune to different parts of India. Each container will be carrying at least 280-300 boxes with each box having 1.20 lakh doses of Covishield.
Source - The Economic Times
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.